The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Practice-changing abstracts in indolent lymphoma at EHA 2020

Jul 21, 2020

During the 25th European Hematology Association (EHA) Annual Congress, the Lymphoma Hub was happy to speak to Martin Dreyling, University of Munich, Munich, DE, who outlined the practice-changing abstracts in indolent lymphoma.

Practice-changing abstracts in indolent lymphoma at EHA 2020

Martin Dreyling highlights three particular areas that he believes will shape the treatment of indolent lymphomas in the near future:

  1. Ibrutinib versus a second generation BTKi for the treatment of Waldenström macroglobulinemia
  2. Triplet regimen (ibrutinib + venetoclax + obinutuzumab) for the treatment of mantle cell lymphoma
  3. CAR T-cell therapy for the treatment of follicular lymphoma